{"filings":[{"id":1829236,"accession_number":"0001323885-26-000032","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-07-23T20:00:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q2 2026 revenue $153.6M (+12.8% YoY); net income $9.0M vs loss a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $153.6M, up 12.8% YoY (12.4% constant currency); U.S. revenue $125.6M (+13.6%).","Net income $9.0M ($0.18 EPS) vs net loss of $0.13 per share in Q2 2025; adjusted EBITDA $27.3M (+78%).","Gross margin 77.2%, up 269 bps YoY; income from operations $9.7M vs loss of $6.2M.","Growth driven by cryoSPHERE MAX pain management probe, EnCompass clamp, AtriClip devices; international revenue $28.0M (+9.6%).","Advancing BoxX-NoAF and LeAAPS clinical trials towards data readouts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":527358,"accession_number":"0001323885-26-000025","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-05-19T20:21:39+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AtriCure shareholders approve share increases for 2023 Stock Incentive Plan and 2018 ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares from 4.5M to 6M.","Shareholders approved amendment to 2018 Employee Stock Purchase Plan, increasing authorized shares by 750,000.","All nine director nominees elected; Deloitte ratified as auditor; say-on-pay approved with over 40M votes.","Stock plan amendment passed with ~41M for vs 1.1M against; broker non-votes of 3.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92090,"accession_number":"0001323885-26-000020","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K/A","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $141.2M (+14.3%); corrects FY2026 guidance to rev $600-610M, adj EBITDA $80-82M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $141.2M (+14.3% YoY); net income $0.1M, breakeven EPS.","U.S. rev growth 14.9% driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp.","Adjusted EBITDA $17.1M, up 95% YoY; gross margin 77.4% (+246 bps).","Corrected FY2026 guidance: revenue $600-610M, adj EBITDA $80-82M, adj EPS $0.09-0.15, net EPS $0.00-0.04.","International revenue $25.0M (+11.5% as reported; +3.3% constant currency)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":141249000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92091,"accession_number":"0001323885-26-000018","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 2026 revenue $141.2M (+14.3%); net income $0.1M; adj. EBITDA $17.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $141.2M (+14.3% YoY); U.S. $116.2M (+14.9%), international $25.0M (+11.5%).","Gross margin 77.4% (+246 bps); income from operations $0.5M vs loss of $6.0M in Q1 2025.","Net income $0.1M; EPS breakeven at $0.00 (vs net loss $0.14 in Q1 2025).","Adjusted EBITDA $17.1M, up 95% from $8.8M in Q1 2025.","No GAAP-to-non-GAAP reconciling items; adjusted EPS also $0.00."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":141249000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102649,"accession_number":"0001323885-26-000005","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.","FY 2025 revenue $534.5M (+14.9% YoY); net loss $11.4M ($0.24 loss per share) improved from $0.95 loss per share in 2024.","FY 2025 adjusted EBITDA $61.8M (+98% vs $31.1M in 2024); Q4 adj. EBITDA $19.9M vs $12.7M.","FY 2026 guidance: revenue ~$600-610M (12-14% growth); adj. EBITDA $80-82M; positive net income; adj. EPS $0.09-0.15.","U.S. revenue $435.4M (+13.7%); international $99.2M (+20.2%); growth driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":534528000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102648,"accession_number":"0001193125-26-009814","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).","FY 2025 revenue $534.5M (+15% YoY); adj. EBITDA $57-59M; adj. loss per share $0.18-0.21.","Ended 2025 with $167M cash; expects positive cash flow and net income in 2026.","2026 revenue guidance $600-610M (+12-14%); adj. EBITDA $80-82M.","Amended credit facility extended 3 years, reduced interest rate, removed minimum utilization covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":534528000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118884,"accession_number":"0001323885-25-000098","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 revenue +15.8% to $134.3M, net loss narrows to $0.3M; raises 2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $134.3M (+15.8% YoY); U.S. $109.3M (+14.5%), international $25.0M (+22.0%).","Net loss of $0.3M ($0.01 diluted EPS) improves $7.6M YoY; adjusted EBITDA $17.8M (+$9.9M).","Gross margin 75.5% (+59 bps) on favorable product mix; operating income $0.2M vs loss of $7.4M.","Company raises full-year 2025 financial outlook (specific guidance numbers not disclosed in press release)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":394028000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118883,"accession_number":"0001323885-25-000101","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K/A","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 revenue $134.3M (+15.8% YoY); net loss narrows to $0.3M; raises FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $134.3M, +15.8% YoY (+15.1% constant currency); US $109.3M (+14.5%), intl $25.0M (+22.0%).","Net loss $0.3M vs $7.9M loss in Q3 2024; GAAP EPS loss $0.01 vs $0.17; adjusted EBITDA $17.8M (+$9.9M).","Generated $30.1M cash in Q3, $25.1M YTD; raised full-year 2025 financial outlook.","Key product drivers: AtriClip FLEX-Mini, EnCompass clamp, cryoSPHERE MAX probe for pain management.","Gross margin 75.5%, up 59 bps YoY on favorable product mix."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":394028000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135429,"accession_number":"0001323885-25-000092","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).","Net loss $6.2M, improved $1.8M YoY; adjusted EBITDA $15.4M, up $7.6M YoY.","Basic/diluted EPS loss $0.13 vs $0.17; adjusted EPS loss $0.02 vs $0.17.","Completed enrollment of 6,500 patients in the LeAAPS trial.","Company raised full-year 2025 financial outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":259759000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152416,"accession_number":"0001323885-25-000050","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AtriCure shareholders approve 1.7M share increase in 2023 Stock Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 2.8M to 4.5M.","All 9 director nominees elected; auditor Deloitte ratified; say-on-pay passed with ~78% support.","Advisory vote on frequency of say-on-pay resulted in one-year frequency; board adopts annual votes.","The plan amendment increases share pool by 1.7M shares (60.7% increase)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152415,"accession_number":"0001323885-25-000041","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $123.6M (+13.6% YoY); net loss improves to $6.7M from $13.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $123.6M (+13.6% YoY; +14.1% constant currency); U.S. $101.1M (+12.1%), International $22.5M (+20.8%).","Net loss $6.7M ($0.14 per share) improved from $13.2M ($0.28 per share) a year ago.","Adjusted EBITDA $8.8M, up from $2.8M in Q1 2024; gross margin 74.9% (+27 bps).","Growth driven by EnCompass clamp, cryoSPHERE MAX probes, AtriClip Flex-Mini device launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":123620000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171247,"accession_number":"0001323885-25-000033","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AtriCure holds 2025 Investor Day; presentation details not provided in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor Day held March 26, 2025 at Mason, OH headquarters from 1-4 p.m. ET.","CEO Michael Carrel presented; no specific financial targets or guidance changes cited.","Exhibit 99.1 presentation file is referenced but only a title fragment was included in the user input."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171246,"accession_number":"0001323885-25-000005","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q4 revenue $124.3M (+16.6% YoY); guides FY25 rev $517-527M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $124.3M (+16.6%); full year revenue $465.3M (+16.5%).","Q4 GAAP net loss $0.33/sh; adj. loss $0.08/sh; adj. EBITDA positive $12.7M.","Full year 2024 adj. EBITDA $31.1M (vs $19.4M in 2023); adj. loss $0.67/sh (vs $0.75).","Launched cryoSPHERE+, cryoSPHERE MAX, AtriClip FLEX-Mini in US, EnCompass clamp in Europe.","FY2025 guidance: rev $517-527M; adj. EBITDA $42-44M; adj. loss $0.57-0.64/sh."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":465307000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171245,"accession_number":"0001323885-25-000002","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).","U.S. revenue $101.6M (+14%), international $22.7M (+28%) in Q4.","FY2024 revenue $465.3M (+17%); expects adj. EBITDA $26M-$29M and adj. EPS loss $0.74-$0.80.","2025 guidance: revenue $517M-$527M, adj. EBITDA $40M-$44M, modest cash flow generation.","Analyst & Investor Day scheduled for March 26, 2025 at Mason, Ohio headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":465307000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188223,"accession_number":"0001323885-24-000115","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).","Net loss per share $0.17 vs $0.20 YoY; adjusted EBITDA $7.9M, up $3.2M from Q3 2023.","Gross margin 74.9%, down 27 bps YoY due to unfavorable product/geographic mix.","Generated $16.3M cash flow from operations in the quarter.","Launched new products; growth driven by open ablation, appendage management, and pain management."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":341030000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204709,"accession_number":"0001323885-24-000104","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).","Gross margin 74.7%, down 168 bps YoY due to mix and product costs; operating loss $7.2M vs $4.1M loss.","Net loss per share $0.17 vs $0.11; adjusted EBITDA $7.8M, down $0.2M vs Q2 2023.","Generated positive cash flow of $8.1M during the quarter.","CEO cited strong growth from pain management and AtriClip franchises; advancing LeAAPS trial and new product launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":225120000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221559,"accession_number":"0001323885-24-000068","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"AtriCure shareholders approve increase in authorized shares under 2023 Stock Incentive Plan to 2.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 1,000,000 to 2,800,000.","Shareholders approved amendment to certificate of incorporation to limit officer liability under Delaware law.","Nine director nominees elected; Deloitte ratified as auditor; say-on-pay approved with 35.6M for vs 6.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221558,"accession_number":"0001323885-24-000060","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).","GAAP net loss $0.28 per share vs $0.14 loss in Q1 2023; operating loss $10.9M (includes $4M prior-year legal settlement gain).","Adjusted EBITDA $2.8M vs $1.9M a year ago; adjusted loss per share $0.25 vs $0.23.","Gross margin 74.7%, up 21 bps YoY on favorable product/geographic mix.","CEO cites strong start with growth across all franchises; new product launches and clinical research ahead."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":108851000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241095,"accession_number":"0001323885-24-000020","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K/A","filed_at":"2024-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AtriCure amends 8-K to add director Shlomi Nachman to two board committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shlomi Nachman elected to Board on Jan 4, 2024, as previously reported.","Effective Feb 22, 2024, Nachman appointed to Strategy Committee and Compliance, Quality and Risk Committee.","Amendment filed to disclose committee assignments not included in original 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241098,"accession_number":"0001323885-24-000013","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q4 revenue $106.5M (+21%), full-year adj EBITDA positive $19.4M; guides 2024 rev ~$459-466M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $106.5M (+21% YoY); full-year revenue $399.2M (+20.8%).","Full-year 2023 net loss improved $16M to $30.4M; adjusted EBITDA turned positive to $19.4M from -$2.2M.","Full-year diluted net loss per share $0.66 vs $1.02 in 2022; adjusted loss per share $0.75 vs $1.02.","2024 revenue guidance $459-$466M (15-17% growth); adjusted EBITDA $26-$29M (34-49% increase).","Over one million patients treated life to date; management cites broad-based expansion and momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":399245000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241097,"accession_number":"0001193125-24-003922","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","9.01"],"status":"ready","headline":"AtriCure prelim Q4 rev $106.5M (+21% YoY); new $125M ABL credit facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 preliminary revenue $106.5M (+21% YoY); full year revenue $399.2M (+21% YoY).","FY2023 adj EBITDA guided $18-20M; adj loss per share ~$0.74-$0.76.","FY2024 revenue guidance $459-466M (15-17% growth); adj EBITDA $26-29M.","New $125M ABL credit facility (up to $165M) replaces SVB facility, enhances liquidity.","CEO cites strong Hybrid AF therapy growth; company positioned for robust 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":399245000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241096,"accession_number":"0001323885-24-000004","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AtriCure appoints former J&J executive Shlomi Nachman to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shlomi Nachman elected to AtriCure Board effective January 4, 2024.","Nachman brings >25 years med device experience; was J&J Company Group Chairman for Cardiovascular and Specialty Solutions.","He is an independent director per NASDAQ standards.","He currently serves on boards of several private med device companies and the Beckman Foundation.","CEO Michael Carrel says Nachman's experience in Afib market will be invaluable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258574,"accession_number":"0001323885-23-000107","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 revenue $98.3M (+18% YoY); positive adjusted EBITDA $4.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $98.3M, up 18.1% YoY; U.S. $81.7M (+17.1%), International $16.6M (+23.2%).","Net loss of $9.1M, improved $3.2M YoY; GAAP EPS loss $0.20, same as adjusted.","Positive adjusted EBITDA of $4.7M vs. negative $0.7M in Q3 2022, an improvement of $5.4M.","FY2023 revenue guidance $394M-$396M (19-20% growth); adjusted EBITDA $18M-$20M.","Gross margin 75.2%, up 110 bps YoY, driven by operational efficiencies and production leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":292702000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275874,"accession_number":"0001323885-23-000094","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q2 revenue $100.9M (+19.4% YoY); net loss narrows to $5.1M, adjusted EBITDA positive $8.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $100.9M, up 19.4% YoY; U.S. $84.9M (+19.1%), international $16.0M (+20.7%).","Net loss of $5.1M, improvement of $9.7M vs Q2 2022; EPS loss $0.11 vs $0.32.","Gross margin 76.4%, up 130 bps YoY; adjusted EBITDA positive $8.0M, up from -$3.2M.","FY 2023 guidance: revenue $392M-$395M (19-20% growth), adjusted EBITDA ~$12M positive.","Adjusted loss per share guided at $0.92-$0.94 for full year 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":194412000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293491,"accession_number":"0001323885-23-000053","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 2023 equity plan and ESPP increase by 750K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2023 Stock Incentive Plan approved with 38.1M for, 2.3M against, 28K abstain.","ESPP amendment approved, increasing authorized shares by 750,000; votes 40.3M for.","All eight director nominees elected with majority votes (e.g., Michael Carrel 38.7M for).","Deloitte & Touche ratified as independent auditor for FY2023 (42.1M for).","Say-on-pay advisory vote passed with 33.7M for, 6.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293490,"accession_number":"0001323885-23-000045","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $93.5M (+25.4% YoY), net loss narrows to $6.5M, positive adj. EBITDA $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $93.5M (+25.4% YoY); US $78.2M (+25.6%), Intl $15.3M (+24.4%).","Net loss $6.5M improved $8.7M YoY; diluted EPS loss $0.14 vs $0.33.","Adjusted EBITDA positive $1.9M vs negative $4.2M in prior year.","FY 2023 revenue guidance $385-392M (17-19% growth); adj. EBITDA ~$2M; adj. EPS loss $1.10-$1.15.","Gross margin 74.5% flat YoY; operating loss $5.8M improved from $14.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":93494000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314125,"accession_number":"0001323885-23-000012","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q4 revenue $88M (+20.2% YoY); FY2022 revenue $330.4M (+20.4%); guides FY2023 rev $380-387M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $88.0M, up 20.2% YoY; U.S. revenue $73.9M (+20.7%), international $14.1M (+17.8%).","Q4 gross margin 74.0% (vs 75.1% prior year); loss from operations improved to $4.1M from $12.5M.","Q4 adjusted EBITDA turned positive at $6.0M (vs -$2.1M); adjusted loss per share $0.09 (vs $0.30).","FY2022 revenue $330.4M (+20.4%); U.S. $277.2M (+21.0%), international $53.2M (+17.7%).","FY2023 guidance: revenue $380-387M (15-17% growth); adjusted EBITDA break-even; adjusted loss per share $1.14-$1.19."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":330379000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314124,"accession_number":"0001323885-23-000008","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtriCure reports Q4 2022 preliminary revenue $88M (+20% YoY); guides 2023 rev $380-387M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue ~$88M (U.S. $73.9M, intl $14.1M), up 20% YoY.","FY2022 revenue $330.4M, up 20% YoY; adjusted EBITDA loss ~$4M.","Adjusted loss per share for FY2022 estimated at $1.10–$1.12.","2023 guidance: revenue $380–$387M, growth 15–17%; EBITDA breakeven.","CEO cites strong demand across product lines; outlook reflects continued momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":330379000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332559,"accession_number":"0001323885-22-000113","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 revenue $83.2M (+18.1% YoY); net loss $0.27/share; guides FY2022 rev ~$328-333M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $83.2M, up 18.1% YoY (19.8% constant currency). US revenue $69.8M (+21.3%).","Gross margin flat at 74.1%; operating loss $10.7M vs income $98.7M in Q3 2021 (includes non-recurring items).","Adjusted EBITDA negative $0.7M vs positive $0.7M last year; adjusted EPS loss $0.27 vs $0.23.","FY 2022 guidance: revenue ~$328-333M (20-21% growth), adjusted EBITDA loss ~$4M, adjusted loss per share ~$1.10-$1.12.","Growth driven by cryoSPHERE pain management, AtriClip Flex·V, and EnCompass clamp; international growth in Australia and Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":242351000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350030,"accession_number":"0001323885-22-000097","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtriCure Q2 2022 revenue $84.5M (+18.4%); net loss $0.32/share; FY guidance unchanged","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $84.5M (+18.4% YoY; +19.8% constant currency); U.S. $71.3M (+18.6%), international $13.3M (+17.3%).","Gross margin 75.1% vs 75.8% prior; operating loss $13.7M vs $15.1M prior.","Net loss per share $0.32 (adjusted $0.32) vs $0.36 GAAP and $0.30 adjusted prior year.","Adjusted EBITDA loss $3.2M vs $2.7M prior; FY 2022 revenue guide $323M-$333M (18-21% growth).","Growth driven by cryoSPHERE, AtriClip, ENCOMPASS, and EPi-Sense products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":159105000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367148,"accession_number":"0001323885-22-000063","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AtriCure shareholders approve 1.1M share increase to stock incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2014 Stock Incentive Plan increasing authorized shares from 5,250,000 to 6,350,000.","All nine director nominees elected; votes ranged from 39.5M to 41.1M in favor.","Ratification of Deloitte & Touche as auditor for FY2022 received 42.8M votes for, 0.5M against.","Advisory vote on named executive officer compensation passed with 39.7M for, 1.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367147,"accession_number":"0001323885-22-000055","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $74.6M (+25.8% YoY); guides FY22 rev $318-330M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $74.6M, up 25.8% YoY; U.S. $62.3M (+23.8%), intl $12.3M (+37.2%).","Gross margin 74.5% vs 75.1% YoY; operating loss narrowed to $14.2M from $15.9M.","GAAP net loss $0.33/share; adjusted loss $0.33/share; adj EBITDA loss $4.2M.","FY 2022 rev guidance $318-330M (+16-20%); adj EPS loss $1.07-$1.12.","CEO cites broad-based growth; EPi-Sense adoption, Cryo Nerve Block expansion, EnCompass launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":74576000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367146,"accession_number":"0001323885-22-000047","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AtriCure launches EnCompass Clamp for cardiac ablation in US","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA 510(k) clearance for cardiac tissue ablation; features parallel closure, uniform pressure, custom RF power.","Magnetic guide enables easier placement with minimal dissection; designed for closed-atrium cardiac surgery.","CEO states clamp provides simpler, faster approach; surgeon cites single-pass efficiency for posterior wall lesions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386527,"accession_number":"0001323885-22-000008","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q4 revenue $73.2M (+26.8% YoY); guides FY22 rev $315-330M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $73.2M (+26.8% YoY); U.S. $61.2M (+29.1%), Intl $12.0M (+16.3%).","FY2021 revenue $274.3M (+32.8%); GAAP net income $1.11/shr; adj loss per share $1.16.","FY2021 includes $184.8M credit for contingent consideration change and $82.3M IPR&D impairment.","FY2022 revenue guidance $315-330M (15-20% growth); adj EBITDA loss $2-4M; adj loss/shr $1.07-1.12.","Milestones: Hybrid Therapy FDA approval, ENCOMPASS 510(k), Cryo Nerve Block expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":274329000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386526,"accession_number":"0001323885-22-000003","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtriCure reports preliminary Q4 revenue $73.2M (+27% YoY), guides FY2022 $315-330M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue ~$73.2M (+27% YoY); U.S. $61.2M (+29%), Intl $12.0M (+16% as reported).","Full year 2021 revenue $274.3M (+33% YoY); adj. EBITDA loss ~$10M, adj. loss per share ~$1.20.","Management guides FY2022 revenue $315-330M (15-20% growth over 2021), subject to pandemic uncertainty.","Preliminary, unaudited results – final audited results with GAAP reconciliation to follow in later release."],"consensus_eps_estimate":null,"consensus_eps_actual":1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":274329000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404447,"accession_number":"0001323885-21-000048","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 revenue $70.5M, +28.7% YoY; adj EPS -$0.23; FY guide reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $70.5M, up 28.7% YoY (28.6% constant currency); U.S. $57.5M (+28.7%), intl $12.9M (+28.5%).","GAAP income from operations $98.7M vs loss $4.0M, driven by $189.9M fair value credit and $82.3M impairment charge.","Adjusted EBITDA $0.7M positive vs $4.2M positive; adjusted loss per share $0.23 vs $0.11 loss.","Maintains FY2021 revenue guidance $270-275M (~31-33% growth); adj EBITDA loss ~$10M; adj EPS loss ~$1.20.","CEO cites growth in Cryo Nerve Block and Hybrid AF accounts; delta variant impacts felt across the country."],"consensus_eps_estimate":null,"consensus_eps_actual":1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":201111000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423444,"accession_number":"0001323885-21-000041","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).","Net loss per share $0.36; adjusted loss per share $0.30; adjusted EBITDA loss $2.7M.","FY2021 revenue guidance raised to $270-275M (growth ~31-33%); adjusted loss per share guidance ~$1.20.","aMAZE trial failed primary efficacy endpoint; safety endpoint met. Potential material adjustments expected in H2 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}